A practical reference on peptide content: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-10. Anything still debated is marked as such rather than presented as settled.
Quality control for peptides involves setting specifications for identity, purity, and counterion content. Batches are tested against these specifications before release. Purity specifications often require a minimum area percentage by high-performance liquid chromatography, such as 95% or 98%, depending on the intended application. Additional tests may include water content, acetate or trifluoroacetate content, and residual solvents. These parameters affect the net peptide content and the accuracy of subsequent laboratory experiments.
Stability testing examines how peptide purity changes over time under defined conditions. Accelerated studies use elevated temperatures and humidity to predict degradation pathways, while long-term studies store samples at recommended temperatures. Common degradation reactions include oxidation of methionine, deamidation of asparagine, and hydrolysis of peptide bonds. The results inform expiration dates and storage recommendations for research materials. Lyophilized peptides are generally more stable than solutions, but both forms can degrade if exposed to moisture, oxygen, or repeated freeze-thaw cycles.
Handling practices strongly affect measured purity and sample integrity. Many peptides are hygroscopic, susceptible to oxidation, or prone to adsorption on glass and plastic surfaces. Lyophilized powders are typically stored desiccated at -20 °C or below, while solutions may require colder storage and minimized freeze-thaw cycles. Peptides containing cysteine, methionine, or tryptophan can degrade through oxidation or disulfide exchange. Working aliquots reduce repeated exposure to moisture and temperature fluctuations during routine analysis.
Purity values do not necessarily predict biological potency. Net peptide content corrects for counterions such as acetate or trifluoroacetate, water, and residual salts. Impurity thresholds for reporting, identification, and qualification are often set according to regulatory guidance, though specific limits depend on the product class and route of administration. Open questions remain about the toxicological relevance of low-level peptide impurities and about how best to compare results across different analytical platforms. A certificate of analysis should state the methods used and the basis for each reported value.
Peptide purity testing sits within a broader quality control framework. Release testing commonly includes appearance, identity, purity, peptide content, counterion content, water content, and residual solvents. Elemental impurities and microbiological attributes may be examined when relevant to the manufacturing route. Pharmacopoeial monographs and general chapters provide methods and acceptance criteria for some peptides, but many research-grade materials are not covered by such standards. Method validation establishes specificity, linearity, accuracy, precision, range, and robustness for each test.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature (lyophilized) | -20 °C | Long-term storage; -80 °C for extended periods |
| Typical storage temperature (solution) | -80 °C | Avoid repeated freeze-thaw; aliquot before freezing |
| Common degradation pathway | Oxidation of methionine | Affects peptides containing methionine; accelerated by oxygen |
| Common counterion | Trifluoroacetate | From HPLC purification; acetate also common |
| Purity specification (research grade) | ≥95% by HPLC area | Higher grades may require ≥98%; method-dependent |
Reversed-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. Separation depends on interactions between peptide residues and a hydrophobic stationary phase, with gradients of water and organic solvent. Ultraviolet detection near 214 nm responds to the peptide backbone and to many related impurities. The resulting chromatogram is often expressed as area percent, which reports the proportion of peak area assigned to the main component. Different columns, gradients, and wavelengths can produce different purity values for the same material.
Mass spectrometry provides complementary information about molecular identity and certain impurities. Electrospray ionization and matrix-assisted laser desorption/ionization are common ionization techniques for peptides. A measured mass close to the expected value supports correct sequence length and modifications, while extra mass signals can reveal truncations, adducts, or incomplete deprotection. Mass spectrometry alone is not a quantitative purity assay, because ionization efficiency varies between compounds. Coupling liquid chromatography to mass spectrometry links retention time with mass and helps assign peaks that ultraviolet detection records.
Orthogonal separation methods address impurities that RP-HPLC may not resolve. Size-exclusion chromatography detects aggregates and higher-order species, while ion-exchange chromatography separates charge variants. Capillary electrophoresis can assess charge-to-mass ratios and, in some formats, size-based impurities. Amino acid analysis and nitrogen determination estimate peptide content rather than chromatographic purity. Because each technique has a different selectivity, a complete purity profile usually combines results from more than one method. The choice of method depends on the impurity classes of concern.
Solid-phase peptide synthesis can produce truncated sequences when coupling reactions fail. Deletion peptides lack one or more internal residues, while truncation peptides end prematurely. Side reactions include aspartimide formation, oxidation of methionine, and aggregation during chain assembly. Crude synthetic peptides therefore contain target peptide plus related impurities, counterions, residual solvents, and water. Purification by preparative chromatography reduces these impurities but does not remove every closely related species, including some that differ by a single amino acid.
Quality control specifications for peptides typically include appearance, identity, purity by RP-HPLC, water content, counterion content, and residual trifluoroacetic acid. Karl Fischer titration measures water, while ion chromatography or elemental analysis can quantify counterions. Purity specifications may be set at 95% or 98% area percent, but the appropriate threshold depends on the application. For research reagents, a lower purity may be acceptable if identity is confirmed. For assays sensitive to impurities, higher purity and orthogonal testing are often required.
Handling and storage influence measured purity, and peptides can oxidize, deamidate, aggregate, or adsorb to surfaces over time. Lyophilized powders stored at -20 °C or lower are generally more stable than solutions, though some sequences require different conditions. Repeated freeze-thaw cycles can promote aggregation and loss, so testing after storage checks whether purity has changed. Stability-indicating methods compare stressed and unstressed samples to detect degradation pathways. Light exposure and pH can also accelerate modification.
Reported purity values can differ between laboratories even for the same sample. Variations arise from column chemistry, mobile-phase composition, gradient slope, detection wavelength, injection load, and integration rules. Area percent also assumes that all species have similar response factors, which is not always true. Method validation examines specificity, linearity, accuracy, precision, limit of detection, and limit of quantitation. When comparing certificates, the method description and representative chromatogram are as important as the headline percentage.
Purity and potency are related but distinct concepts in peptide testing. Purity describes the proportion of the main peptide relative to other detected substances, while potency refers to the biological or functional activity of a defined amount. A highly pure peptide can still have low potency if it is misfolded, aggregated, or chemically modified at a critical residue. Conversely, a less pure preparation may retain high activity if the impurities are inactive. Clear reporting separates these attributes and states the assay used for each.
Interpreting chromatographic purity requires attention to detection limits and response factors. Peptides without aromatic residues may absorb weakly at 280 nm, so 214 nm is often preferred, but mobile-phase additives and solvents also absorb at low wavelengths. Co-eluting impurities with different molar absorptivities can produce area percentages that differ from mass percentages. Integration parameters, peak tailing, and baseline choice further affect reported values. For these reasons, method details belong alongside any purity figure, and orthogonal methods are needed to confirm identity and impurity profiles.
Reverse-phase high-performance liquid chromatography is the most common primary method for peptide purity testing. The peptide mixture passes through a hydrophobic stationary phase, and components elute according to differences in hydrophobicity. A mobile phase of water and acetonitrile, often with trifluoroacetic acid as an ion-pairing agent, improves peak shape and retention. Ultraviolet detection at 214 nm records the peptide backbone absorbance, and the main peak area is divided by the total peak area to give an area-percent purity value.
Other chromatographic modes provide complementary information that reverse-phase separation may not capture. Ion-exchange chromatography separates peptides by net charge and can resolve deamidated, oxidized, or truncated variants that co-elute under hydrophobic conditions. Size-exclusion chromatography detects aggregates and higher-order oligomers, which are often invisible in reverse-phase assays. Chiral chromatography can quantify D-amino acid epimers when stereochemical purity matters. Because each mode uses a different separation principle, a single purity number from one method cannot describe all possible impurities.
In the absence of other glucogenic sources, the 2-carbon acetyl-CoA derived from the oxidation of fatty acids cannot produce a net yield of glucose via the citric acid cycle, since an equivalent two carbon atoms are released as carbon dioxide during the cycle. During ketosis, however, acetyl-CoA from fatty acids yields ketone bodies, including acetone, and up to ~60% of acetone may be oxidized in the liver to the pyruvate precursors acetol and methylglyoxal. Thus ketone bodies derived from fatty acids could account for up to 11% of gluconeogenesis during starvation. Catabolism of fatty acids also produces energy in the form of ATP that is necessary for the gluconeogenesis pathway.
In chromatography substances are separated by partition between a stationary phase and a mobile phase. The analyte is dissolved in the mobile phase, and passes over the stationary phase. Separation occurs because of differing affinities of the analytes for the stationary phase. A distribution constant, Kd can be defined as
Blood levels necessary to cause adverse effects in adults are thought to be greater than about 150 ng/mL. An excess of vitamin D causes hypercalcaemia (high blood concentrations of calcium), which can cause overcalcification of the bones and soft tissues including arteries, heart, and kidneys. Untreated, this can lead to irreversible kidney failure. Symptoms of vitamin D toxicity may include the following: increased thirst, increased urination, nausea, vomiting, diarrhea, decreased appetite, irritability, constipation, fatigue, muscle weakness, and insomnia. In 2011, the US National Academy of Medicine revised tolerable upper intake levels (UL) to protect against vitamin D toxicity. Before the revision the UL for ages 9+ years was 50 μg/d (2000 IU/d). Per the revision: "UL is defined as "the highest average daily intake of a nutrient that is likely to pose no risk of adverse health effects for nearly all persons in the general population". The US ULs in micrograms (mcg or μg) and international units (IU) for both males and females, by age, are:
Elizabeth Broadbent; Keith J Petrie; Jodie Main; John Weinman (2006). "The brief illness perception questionnaire". Journal of Psychosomatic Research. 60 (6): 631–637. doi:10.1016/j.jpsychores.2005.10.020. PMID 16731240. Wikidata Q50936509. Elizabeth Broadbent; Carissa Wilkes; Heidi Koschwanez; John Weinman; Sam Norton; Keith J Petrie (2015). "A systematic review and meta-analysis of the Brief Illness Perception Questionnaire". Psychology & Health. 30 (11): 1361–1385. doi:10.1080/08870446.2015.1070851. PMID 26181764. Wikidata Q38548518. E. Broadbent; R. Stafford; B. MacDonald (2009). "Acceptance of Healthcare Robots for the Older Population: Review and Future Directions". International journal of social robotics. 1 (4): 319–330. doi:10.1007/s12369-009-0030-6. Wikidata Q115258302. Hayley Robinson; Bruce Macdonald; Ngaire Kerse; Elizabeth Broadbent (2013). "The psychosocial effects of a companion robot: a randomized controlled trial". Journal of the American Medical Directors Association. 14 (9): 661–667. doi:10.1016/j.jamda.2013.02.007. PMID 23545466. Wikidata Q45166572. Elizabeth Broadbent; Liesje Donkin; Julia C Stroh (2011). "Illness and treatment perceptions are associated with adherence to medications, diet, and exercise in diabetic patients". Diabetes Care. 34 (2): 338–340. doi:10.2337/dc10-1779. PMC 3024345. PMID 21270191. Wikidata Q34507111.
Sources: en.wikipedia.org
== As therapeutic targets == Modulation of PPI is challenging and is receiving increasing attention by the scientific community. Several properties of PPI such as allosteric sites and hotspots, have been incorporated into drug-design strategies. Nevertheless, very few PPIs are directly targeted by FDA-approved small-molecule PPI inhibitors, emphasizing a huge untapped opportunity for drug discovery. In 2014, Amit Jaiswal and others were able to develop 30 peptides to inhibit recruitment of telomerase towards telomeres by utilizing protein–protein interaction studies. Arkin and others were able to develop antibody fragment-based inhibitors to regulate specific protein-protein interactions. As the "modulation" of PPIs not only includes the inhibition, but also the stabilization of quaternary protein complexes, a paradigm introduced by the discovery of auxin-induced protein complex formation by Ning Zheng, molecules with this mechanism of action (so called molecular glues) are also extensively studied.
A similar platform was used for the SCIEX AROMIC system (part of the CONDOR contraband detection system developed together with British Aerospace) for the detection of drugs, explosives and alcohol in shipping containers at border crossings, by sampling the interior airspace. In the mid-1980s and into the early 1990s, the advantages of performing LC/MS with APCI and with electrospray, both atmospheric pressure ionization techniques, began to capture the attention of the analytical community. Together they have dramatically expanded the role of mass spectrometry in the pharmaceutical industry for both drug development and drug discovery applications. The sensitivity of APCI combined with the specificity of LC-MS and LC-MS/MS often makes it the method of choice for the quantification of drugs and drug metabolites.
International law experts argued that the operation may have violated international law. On 3 January 2026, United Nations Spokesperson Stéphane Dujarric issued a statement that said the UN Secretary-General António Guterres was "deeply alarmed by the recent escalation in Venezuela" and that United States' military action "has potential worrying implications for the region". Lawyer Geoffrey Robertson stated that the strike on Venezuela was contrary to Article 2(4) of the UN Charter and qualifies as a crime of aggression under international law. Elvira Domínguez-Redondo, professor of international law at Kingston University, also stated the strike was an act of aggression and that it could only have been lawful if it had authorization by a United Nations Security Council resolution, or was justified as "self-defense", but she added that there was "no evidence whatsoever" to support either condition. Ben Saul, a UN special rapporteur and professor of international law, condemned "the US's illegal aggression against Venezuela and the illegal abduction of its leader and his wife" and called on Trump to be investigated and impeached. Professor of international law Michael N. Schmitt, law professor Ryan Goodman and Tess Bridgeman concluded that the operation against Venezuela "amounts to a severe breach of foundational principles of international law". Professor of law Ziyad Motala described the "intervention in Venezuela to abduct President Nicolás Maduro" as "international vandalism, plain and unadorned".
Sources: en.wikipedia.org
The symptoms of PSSD are largely shared with post-finasteride syndrome and post-retinoid sexual dysfunction, two other poorly understood conditions which have been suggested to share a common etiology with PSSD despite being associated with different types of medication. Diagnostic criteria for PSSD were proposed in 2022, but as of 2023, there is no agreement on standards for diagnosis. It is a distinct phenomenon from antidepressant discontinuation syndrome, post-acute withdrawal syndrome, and major depressive disorder, and should be distinguished from sexual dysfunction associated with depression and persistent genital arousal disorder. There are limited treatment options for PSSD as of 2023 and no evidence that any individual approach is effective. The mechanism by which SSRIs may induce PSSD is unclear. However, various neurochemical, hormonal, and biochemical changes during SSRI use—such as reduced dopamine levels, increased serotonin, inhibition of nitric oxide synthase, and the blocking of cholinergic and alpha-1 adrenergic receptors—could account for their sexual adverse effects. Additionally, SSRIs may cause peripheral changes by inhibiting serotonin receptors in peripheral nerves, which may also play a role in PSSD. As of 2023, prevalence is unknown. A 2020 review stated that PSSD is rare, underreported, and "increasingly identified in online communities". A 19 year retrospective analysis looking at people with erectile dysfunction who met most of the criteria for PSSD found that the estimated risk was 0.46%.
=== Legal status === Datopotamab deruxtecan was approved for medical use in the United States in January 2025. In December 2024, the US Food and Drug Administration granted the application for datopotamab deruxtecan breakthrough therapy designation. In January 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Datroway, intended for the treatment of breast cancer. The applicant for this medicinal product is Daiichi Sankyo Europe GmbH. Datopotamab deruxtecan was authorized for medical use in the European Union in April 2025.
== In vivo activity == NR58-3.14.3 also inhibits the recruitment of leukocytes (macrophages, T cells, B cells) due to the chemokine CCL2 in rat skin. A similar effect was observed using Lipopolysaccharide (LPS) instead of CCL2 (macrophages, neutrophils, T cells, B cells). In addition NR58-3.14.3 inhibits LPS-induced accumulation of tumour necrosis factor-α (TNF-α). This is consistent with the peptide acting as a chemokine inhibitor up-steam of TNF-α productsion and anti-inflammatory in vivo. The cyclic peptide NR58-3.14.3 was shown to be a powerful anti-inflammatory agent in vivo inhibiting inflammation in a number of disease models such as atherosclerosis, ischemia, lung disease, surgical adhesions, endometriosis and pulmonary graft-versus-host disease. It has been suggested that blockage of chemokine function using these molecules should not have a detrimental toxicological effect.
Sources: en.wikipedia.org
Lyophilized peptides are typically stored at -20 °C or lower, protected from moisture and light. Solutions are often stored at -80 °C and divided into single-use aliquots. Repeated freeze-thaw cycles should be avoided.
Oxidation of methionine and deamidation of asparagine are frequent reactions. Hydrolysis of peptide bonds can occur under acidic or basic conditions. Each pathway produces impurities that reduce purity.
Specifications depend on the intended use and supplier. Common minimums are 95% or 98% by HPLC area percentage. Identity and counterion content are also checked.
Lyophilized peptides are generally stored desiccated at -20 °C or lower, protected from light and moisture. Solutions are often kept at -80 °C in aliquots to limit freeze-thaw damage. Specific sequences may require different conditions based on oxidation or aggregation risk.